Osteonecrosis of the jaw after zoledronic acid and denosumab treatment

J Clin Oncol. 2011 Jun 10;29(17):e521-2; author reply e523-4. doi: 10.1200/JCO.2011.35.1551. Epub 2011 May 2.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Bone Density Conservation Agents / adverse effects*
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / secondary
  • Denosumab
  • Diphosphonates / adverse effects*
  • Humans
  • Imidazoles / adverse effects*
  • Incidence
  • Jaw Diseases / chemically induced*
  • Osteonecrosis / chemically induced*
  • Osteonecrosis / epidemiology
  • RANK Ligand / adverse effects*
  • Zoledronic Acid

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • RANK Ligand
  • Denosumab
  • Zoledronic Acid